TITLE:
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

CONDITION:
HIV Infections

INTERVENTION:
Optimized Background ARVs

SUMMARY:

      This study will assess the safety and efficacy of once-daily administration of Fuzeon
      compared with twice-daily administration in HIV-1 infected patients who have received prior
      treatment. Patients will also receive an optimized treatment consisting of antiretroviral
      (ARV) therapy as determined by the treating physician. The anticipated time on study
      treatment is 3-12 months, and the target sample size is 100-500 individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 16 Years to N/A
Criteria:

        Inclusion Criteria:

          -  HIV-1 infected adults or adolescents >=16 years of age;

          -  HIV-1 RNA >=5000 copies/mL;

          -  prior experience or documented resistance to each of the 3 currently available
             classes of ARV drugs (nucleoside reverse transcriptase inhibitors, non-nucleoside
             reverse transcriptase inhibitors, and protease inhibitors).

        Exclusion Criteria:

          -  history of prior use of Fuzeon or T-1249;

          -  female patients who are pregnant or breastfeeding, or who plan to become pregnant
             during the study;

          -  current severe illness;

          -  currently taking drugs affecting the immune system, HIV vaccine, or investigational
             agents for any conditions other than HIV/AIDS.
      
